Thyme Care Raises $97M in Series D Investment

Published by Cancer Letter on Nov 17, 2025 1:21:04 PM

Thyme Care has announced a $97M Series D fundraise from current investors CVS Health Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures.

New strategic investors include Morgan Health, a division of JPMorganChase focused on employer-sponsored healthcare, as well as Humana, Texas Oncology, and Memorial Hermann Health System, bringing Thyme Care’s total capital raised to $275M.

Click here to read the full article.

Back to Blog

Thyme Care was featured in HIT Consultant after raising $97 million to scale its value-based...

HIT Consultant

Thyme Care was recently featured in Becker’s Health IT for closing a $97M Series D funding round....

Becker's Health IT

Thyme Care achieves profitability, manages more than $5B in oncology spend, and extends access to...

Thyme Care Raises $97M in Series D Investment

Click here to read the full article.

Related Articles

Thyme Care Secures $97M to Scale Value-Based Oncology and AI Infrastructure

HIT Consultant

CVS, Memorial Hermann & more raise $97M for oncology AI startup

Becker's Health IT

$97M Series D Backed by Strategic Investors Across the Oncology Ecosystem Positions Thyme Care to Break Through Cancer Care's Biggest Bottlenecks

Thyme Care